Alimentary TractPotential coeliac disease markers and autoimmunity in olmesartan induced enteropathy: A population-based study
Introduction
In 2012 a new non-coeliac sprue-like enteropathy associated with olmesartan was characterized [1]. Since then more than 100 cases have been reported [2], [3], including a cohort of 36 patients in a national survey in France [2]. The clinical picture includes severe diarrhea, frequently life-threatening, requiring hospitalization and treatment in intensive care units. The incidence of this enteropathy in olmesartan-treated patients and the whole spectrum of severity are unknown [4]. It is noteworthy that large phase III trials did not detect gastrointestinal adverse reactions in olmesartan-treated patients compared with those treated with placebo [5], [6]. This discrepancy might be either the short duration of clinical trials, rendering them unable to detect a complication that occurs in medium- or long-term sustained treatment and/or the rarity of this severe entity [4], [5].
The mechanism underlying olmesartan-associated enteropathy is unknown but a high proportion of the reported patients had a genetic predisposition for coeliac disease (CD), ranging from 68 to 77% [1], [2], which is clearly higher than that described in the general population. It was speculated that the presence of HLA-DQ2 or HLA-DQ8 might increase the risk of immune-mediated damage [1]. In addition, a number of patients in the French series had a past history of immune-mediated diseases [2]. However, to the best of our knowledge autoimmune phenomena associated with olmesartan administration have not been reported to date.
Olmesartan is an angiotensin II receptor blocker (ARB) widely used in the treatment of hypertension [7]. Apart from the known vascular effects, angiotensin II receptor AT [2] interferes with proinflammatory pathways including inhibition of cell growth, modulation of extracellular matrix, apoptosis and cellular differentiation [8].
The aims of this study were to: (1) determine the population-based incidence rate of olmesartan enteropathy in the area of Terrassa, Catalonia, Spain, (2) describe the clinical picture of olmesartan-induced enteropathy and other immune disorders, and (3) assess the genetic predisposition of CD and duodenal CD markers that could predispose to olmesartan damage.
Section snippets
Study setting for incidence calculation
The study period for estimating the annual population-based incidence of enteropathy associated with olmesartan was January 2011 to December 2014 and the setting was the catchment area of the Hospital Universitari Mutua Terrassa (HUMT). The hospital is located in north-eastern Spain (Catalonia), and it is of a mixed rural-urban type. On August 15, 2014, the population residing in this geographical area was 251,225 inhabitants (data obtained from the 2014 population census, ‘Institut
Annual incidence rates (period 2011–2014) in the catchment area of Terrassa, Catalonia (Spain)
Between January 2011 and December 2014, 6 patients resident in the catchment area of the HUMT were attended due to severe enteropathy associated with olmesartan. The first case was admitted to the hospital with severe diarrhea and dehydration in May 2011. It was not until 2012, after the publication of Rubio-Tapia [1], that the patient was properly diagnosed. Annual incidence rates (period 2011–2014) are detailed in Table 1. No other similar cases were found among residents in the study area
Discussion
The particular setting of HUMT providing both private and public health services allowed us to learn the epidemiological characteristics of enteropathy associated with olmesartan in the period 2011–2014. Annual cumulative incidence rates showed that might affect up to 22 cases per 10,000 patients treated for at least 6 months. This low incidence may explain why this severe entity has not previously been detected, either in pivotal trials (2232 diabetics treated for 3.2 years in ROAMAP study [5]
Conflict of interest
None declared.
Acknowledgements
The authors are grateful to Mónica Roldán and Meritxell Vendrell (Autonomous University of Barcelona) for their assistance in microscopic visualization, to Natalia Berenice for her technical laboratory support, and to Núria Rubies, Maite Roldan, Olga Benítez, Anabel Polo, and Rosa Tomás for their helpful technical assistance.
The ‘Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas’ (CIBERehd) is an initiative of the Instituto de Salud Carlos III, Madrid, Spain.
References (25)
- et al.
Severe sprue-like enteropathy associated with olmesartan
Mayo Clinic Proceedings
(2012) - et al.
Olmesartan and intestinal adverse effects in the ROADMAP study
Mayo Clinic Proceedings
(2012) - et al.
Angiotensin and its AT2 receptor: new insights into an old system
Regulatory Peptides
(2001) - et al.
Incidence of collagenous and lymphocytic colitis: a 5-year population-based study
American Journal of Gastroenterology
(1999) - et al.
Microscopic colitis: current status, present and future challenges: statements of the European Microscopic Colitis Group
Journal of Crohn's and Colitis
(2012) - et al.
Intestinal deposits of anti-tissue transglutaminase IgA in childhood coeliac disease
Digestive and Liver Disease
(2011) - et al.
Olmesartan, other antihypertensives, and chronic diarrhea among patients undergoing endoscopic procedures: a case–control study
Mayo Clinic Proceedings
(2014) - et al.
Olmesartan-associated enteropathy: results of a national survey
Alimentary Pharmacology and Therapeutics
(2014) - et al.
Systematic review: sprue-like enteropathy associated with olmesartan
Alimentary Pharmacology and Therapeutics
(2014) - et al.
Editorial: sprue-like enteropathy due to olmesartan and other angiotensin receptor blockers – the plot thickens
Alimentary Pharmacology and Therapeutics
(2014)
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes
New England Journal of Medicine
Olmesartan medoxomil: a review of its use in the management of hypertension
Drugs
Cited by (23)
Olmesartan-induced enteropathy
2021, FMC Formacion Medica Continuada en Atencion PrimariaOlmesartan-associated enteropathy: Belgian survey
2021, TherapiesCeliac Disease: Clinical Features and Diagnosis
2019, Gastroenterology Clinics of North AmericaSprue-like enterophaty asscociated with valsartan
2018, Medicina ClinicaImpaired Barrier Function and Autoantibody Generation in Malnutrition Enteropathy in Zambia
2017, EBioMedicineCitation Excerpt :We postulate that in the presence of mucosal T cell activation (Campbell et al., 2003; Veitch et al., 2001) and epithelial leakiness the cells of the lamina propria can generate autoantibodies, and that this autoreactivity exacerbates mucosal pathology. Autoantibody generation has been reported in Crohn's disease (Ribeiro-Cabral et al., 2011) and in olmesartan-induced enteropathy (Esteve et al., 2016) where it was reversible. Exposure to gluten and gliadin peptides is thought to be essential for development of the autoantibodies which characterize coeliac disease (Sollid and Jabri, 2013), but in Zambia the staple diet is maize, and children being treated for SAM have a therapeutic feed which includes no gluten (Ashworth et al., 2003).
Towards better patient care: Medicines to avoid and possible alternatives. Update 2016-2017
2017, FMC Formacion Medica Continuada en Atencion Primaria